INTRODUCTION
A number of clinical and experimental studies have suggested that dipyridamole, a vasoactive substance, can function as an antiplatelet and antithrombotic agent (1) (2) (3) (4) . In addition to these in vivo observations, inhibition of ADP-induced platelet aggregation and release reaction in vitro by dipyridamole has been observed (5, 6) . The drug was previously shown to inhibit platelet phosphodiesterase (7) (8) (9) and the uptake of glucose (6) , and adenosine (10) (11) (12) by platelets. Dipyridamole also potentiated the inhibitory effect of adenosine on ADP-induced platelet aggregation (7, 8, 13) , and it was proposed that this is due to accumulation of adenosine which activates the platelet adenylate cyclase (14) . These observations suggested a relationship between adenosine uptake by platelets and inhibition of ADP-induced platelet aggregation. Further studies on the mechanism of adenosine uptake by platelets and its inhibition by dipyridamole may provide a better understanding of platelet aggregation.
We previously reported that the degree of inhibition of ADP-induced platelet aggregation by dipyridamole was much greater with washed platelet suspension than with platelet-rich plasma (PRP)l (15) . This difference in potency was attributed to a, acid glycoprotein (a, acid GP) of the plasma which interferes with the antiplatelet activity of dipyridamole (15) . ' Abbreviations used in this paper: a, acid GP, a, acid glycoprotein; PPP, platelet-poor plasma; PRP, platelet-rich plasma; RA 233, dipyridamole derivative Thus, the a, acid GP has been implicated in the modification of dipyridamole function as an inhibitor of adenosine uptake by platelets. In a preliminary communication we reported the inhibition of adenosine uptake and aggregation when dipyridamole is bound to platelets (16) . We showed that binding of dipyridamole to washed platelets at 37°C reaches a maximum within 1 min of incubation and is not affected by temperature (4°-50°C) and pH (6) (7) (8) of the incubation mixture (16) . Results concerning the metabolism of [14C]adenosine in platelets in relation to the binding of dipyridamole to platelets and to a, acid GP are reported.
METHODS
Materials. Nonradioactive and passed through a Sepharose 2B column (1 x 25 cm) equilibrated with calcium-free buffer (24). 1.0-ml fractions were collected and analyzed for platelets (with Coulter counter, Coulter Electronics Inc., Hialeah, Fla.) and radioactivity. In another set of experiments, 3.5 ml (2 x 109 cells/ml) of washed human platelet suspension was incubated with dipyridamole (10 ,uM) in a final vol of 4.0 ml at 37°C and subjected to gel filtration. The platelet concentration of the pooled fractions containing >109 cells/ml was adjusted to 109 cells/ml with equilibrating buffer and used for the determinations of [8-14C] adenosine uptake.
Uptake of ['4C]adenosine by human platelets. Washed human platelet suspension or PRP of 0.8 ml (109 cells/ml) was incubated with [8-14C] adenosine (0.1 ,uM) at 37°C for 5 min in a final volume of 1.0 ml. The percent of total radioactivity in the platelet pellet was estimated as described for the binding of [14C]dipyridamole to platelets. Similar uptake measurements were made using platelets incubated with varying concentrations of dipyridamole for 5 min or a, acid GP for 10 min at 37°C. In another set of experiments, platelets were incubated with specified amounts of purified a, acid GP for 10 min before the addition of dipyridamole.
Incorporation of ["'C ladenosine into platelet adenine nucleotides. Washed human platelets or PRP (0.7 ml, 109 cells/ml) were incubated for 5 min at 37°C with uniformly labeled adenosine (0.1 ,uM) in a total volume of 1.0 ml. Aliquots of samples were mixed with equal volumes of 90% ethanol containing 7.7 mM EDTA (pH 7.4) and analyzed for adenosine metabolites by high voltage paper electrophoresis (17) . The radioactivities of adenosine metabolites were estimated using washed platelet suspension and its supernate, or PRP and platelet-poor plasma (PPP). The The radioactivity determinations were made using Intertechnique scintillation spectrometer, model SL 40 (Intertechnique, Dover, N. J.). Scintillation fluid (15 ml/sample) consisted of 0.55% PPO and 0.01% POPOP in toluene, Triton X-100 (1:1, vol/vol). The counting efficiency was 70%.
Calculations. The binding constants (Ka) for the interaction of dipyridamole with platelets were estimated using the equation (25, 26) : (27) . The fraction of binding sites of platelet or that of a, acid GP, occupied by the drug at a
Binding of Dipyridamole to Human Platelets particular concentration of dipyridamole was estimated using the equation described by Paton (28) .
Where Pe is the fraction of binding sites occupied: X is the concentration of dipyridamole and K is equilibrium constant or dissociation constant (Kd).
RESULTS
Binding of dipyridamole to a1 acid GP. Dipyridamole was shown to form a complex with a, acid GP (15) . The molar ratio of both components in the complex was established from the elution profile of [14C]dipyridamole-a1 acid GP mixture applied on Sephadex G-25 ( Fig. 1) . In this figure the area of the peak above the base line corresponds to the amount of [14C]dipyridamole bound to a, acid GP, whereas the area of the trough that follows represents the amount of [14C]dipyridamole removed by a, acid GP from the buffer that equilibrates the gel. The integrated areas are therefore, essentially, equal. As the concentration of dipyridamole that was applied to the column increased from 0 to 66 ,uM, the area of the trough progressively decreased and finally resulted in a positive peak (not illustrated).
Samples with excess dipyridamole in relation to al 10 20 FRACTION NUMBER (ml) Binding of dipyridamole to human platelets. The concentration dependence of dipyridamole binding to washed platelets and its modification by a1 acid GP or PPP is shown in Fig. 2 . The binding of [14C]dipyridamole to platelets was inhibited by 0.25 mg of purified a1 acid GP or 0.2 ml of PPP (plasma contains 0.7-0.9 mg a1 acid GP/ml). As shown in Fig. 2 adenosine by 50%. However, a 1,000-fold higher concentration of the drug (0.5 ,uM) was necessary to produce similar inhibition in PRP (Fig. 4) . Addition of a, acid GP (1 mg/ml) to washed platelet suspension (Fig. 5) increased the 150 value2 of dipyridamole from 0.5 nM to 0.5 ,uM as observed with PRP.
Dipyridamole (0.1 1,M) inhibited adenosine uptake by washed human platelets by >75%, whereas, purified a, acid GP at a concentration of 0.05 and 0.25 mg/ml reversed the inhibitory effect of dipyridamole by 7 whereas, the incorporation of radioactivity into hypoxanthine plus inosine was increased from 24 to 42%. These changes produced by 0.1 uM of dipyridamole The relationship between inhibition of adenosine uptake and binding of dipyridamole to platelets. When washed human platelets (109 cells/ml) were incubated with ['4C]dipyridamole (1 ,M) and subjected to gel filtration on Sepharose 2B column, it was found that the early fractions contained platelets without ['4C]dipyridamole-radioactivity, whereas the latter fractions showed the radioactivity and did not contain platelets (results not included). It is therefore possible to separate [14C]dipyridamole bound to platelets by gel filtration. Recovery of about 95% of total radioactivity was achieved by this method.
The effect of removal of dipyridamole from washed platelets on the inhibition of adenosine uptake by platelets is shown in Table I . The percent of total [14C]adenosine-radioactivity in platelet pellet was estimated using platelet suspension obtained before and after Sepharose 2B gel filtration and compared with similar samples obtained after incubating the platelets with dipyridamole. The gel filtration of platelets alone resulted in a 20% loss in the ability of washed platelets to take up [14C]adenosine. Separation of dipyridamole from washed platelets by gel filtration completely abolished the inhibitory potency of dipyridamole on adenosine uptake by washed human platelets. The binding of dipyridamole to platelets is therefore essential for its inhibition on adenosine uptake by platelets. It was observed that adenosine (10 mM) did not inhibit the binding of dipyridamole (1 ,uM) to washed platelets. (32, 33) . Since dipyridamole binds to erythrocytes (34) , it is possible that the mechanism of inhibition of adenosine uptake by erythrocytes is also related to the binding of dipyridamole to erythrocytes membranes.
The effect of low concentration of dipyridamole on [14C]adenosine uptake and its incorporation into platelet nucleotides could be reversed by a, acid GP of plasma (Fig. 6) . Dipyridamole binds to a, acid GP of plasma forming a complex (15, 35) . In agreement with equilibrium dialysis method (35) , the molar ratio of dipyridamole to a, acid GP as determined by Hummel and Dreyer's method (22) Using a spectrofluorometric method (36) , we estimated the level of circulating dipyridamole in the plasma of 12 human volunteers who ingested several dosages of dipyridamole (0.48-3.6 mg/kg body wt). We also measured the percent inhibition of [14C]adenosine uptake by their platelets. The concentration of dipyridamole required to exert 50% inhibition of [14C]-adenosine uptake by platelets suspended in plasma (PRP) under in vitro and in vivo conditions were found to be of same order of magnitude (0.2-0.5 uM). This indicates that the mode of action of dipyridamole on the adenosine uptake by platelets in vivo probably involves the binding of the drug to high-affinity sites of the platelets.
Since dipyridamole binds to platelets and to a, acid GP of plasma, we suggest that dipyridamole exists in a dynamic state of equilibrium between a, acid GP and platelets. The effect of dipyridamole on adenosine uptake by platelets may therefore depend on the level of circulating drug and on the level of a, acid GP. The level of al acid GP in plasma was shown to vary under different conditions of inflammation and tissue injury (37, 38) . It follows that the pharmacological effectiveness of dipyridamole as inhibitor of adenosine uptake by platelets can be evaluated on the basis of relative concentrations of circulating dipyridamole and a, acid GP in plasma.
The data suggest the presence of binding sites for dipyridamole in platelets that are involved in the adenosine transport across cell surface. Further studies on the isolation and characterization of these sites from platelets may help to explain the adenosine transport mechanism in cells.
